fda warning letter bpc-157 peptide compounding Targets GLP-1 and Compounding, Advertising and 'Research Use Only' Labeling FDA panel backs compounded BPC-157,

It can indicate bacterial contamination, poor quality peptide, or an issue with your diluent

It is not a hormone, not a steroid, not a stimulant

This means the B12 component in a compounded semaglutide formulation is most likely to help patients who are deficient or at risk of deficiency, those eating very little, those following plant-based diets, older adults whose B12 absorption decreases with age, or those with conditions affecting B12 absorption like gastric bypass or certain GI conditions

It makes it an adjunct with a plausible mechanism and thin outcome data, delivered inside a supervised programme

In fibrosis-related contexts, it has also been described as a regulator of pathways related to tissue remodeling[2]